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Clinically, the most common genetic factors associated with male infertility are chro-
mosomal abnormalities, Y chromosome deletion, and cystic fibrosis transmembrane 
conductance regulator (CFTR) gene mutations that are associated with congenital 
bilateral absence of vas deferens (CBAVD). The prevalence of chromosomal abnor-
malities in all infertile men is 5–7%. Patients with azoospermia are likely to possess 
sex chromosome abnormalities, and Klinefelter syndrome (47,XXY) is the most prev-
alent sex chromosome disorder. Conversely, oligozoospermic men are likely to have 
autosomal chromosome abnormalities, which include chromosomal translocation 
and inversion. Y chromosome deletion is the second most frequent genetic cause of 
spermatogenic failure after Klinefelter syndrome. The current deletion model, 
which has been revised according to the recombination mechanisms, includes AZFa, 
P5/proximal P1, P5/distal P1, P4/distal P1 and AZFc (b2/b4) deletions. The overall 
deletion frequency in Taiwanese infertile men is 6.5%, and AZFc (b2/b4) deletion is 
the most common deletion pattern, which does not show an ethnicity-specific dele-
tion pattern in the Taiwanese population. CBAVD accounts for ∼2% of male infertil-
ity and ∼6% of obstructive azoospermia. It has been shown that CBAVD is associated 
with CFTR gene mutation. The mutation spectrum of the CFTR gene in Taiwanese 
CBAVD patients is different from that of the Caucasian population; the Taiwanese do 
not carry the common CFTR mutations found in Caucasians. Polymorphic polythymi-
dine tract in intron 8 5T allele accounts for the majority (81%) of the mutant alleles 
in Taiwanese CBAVD. In conclusion, suggestions for current genetic testing in male 
infertility are as follows: karyotype analysis should be offered to all oligozoospermic 
men; an additional Y chromosome deletion test is recommended for men with se-
vere oligozoospermia (< 5 ˜  106/mL) or non-obstructive azoospermia; and detection 
of CFTR gene mutation status is necessary for men with structural abnormalities of 
the vas deferens. Genetic testing can be helpful for reproductive decision making by 
physicians as well as infertile couples, which might obviate the need for assisted re-
productive techniques and the production of congenital defects in the offspring.
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1.  Introduction
Advances in the intracytoplasmic sperm injection (ICSI) 
technique have resulted in many infertile men achieving 
paternity using a limited number of sperm. However, the 
majority of couples in which the men have severe oligo-
zoospermia or non-obstructive azoospermia still cannot 
achieve pregnancy even with ICSI.1 Possible reasons for 
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this are that the causes of male infertility are unknown 
in up to 25–30% of cases, and that most cases of idio-
pathic male factor infertility are believed to be genetic in 
origin.2–5 In contrast, it has been shown that an increase 
in congenital abnormalities in infants born after ICSI is 
more likely to be linked to the injection of genetically ab-
normal sperm.6 Therefore, genetic factors are frequently 
associated with spermatogenic failure and should play a 
crucial role in male infertility. Although our knowledge 
of the genetic causes of male infertility has increased in 
the past decade, advances in the genetic diagnosis of 
male infertility have been relatively limited. To date, the 
three most common genetic factors that are related to male 
infertility are numerical or structural chromosomal abnor-
malities, Y chromosome deletion, and cystic fibrosis trans-
membrane conductance regulator (CFTR) gene mutations 
that are associated with congenital absence of vas deferens.
2.  Chromosomal Abnormalities
2.1.  Male infertility and chromosomal 
abnormalities
Chromosomal abnormalities can be divided into sex and 
autosomal chromosome abnormalities. It has been esti-
mated that the prevalence of chromosomal abnormalities 
in infertile men is approximately 5.8%, with prevalence 
of sex chromosome abnormalities at 4.2% and autosomal 
chromosome abnormalities at 1.5%.7 An analysis of neo-
natal boys has shown that the prevalence of chromosomal 
abnormalities is 0.38%, with prevalence of sex chromo-
some abnormalities at 0.14% and autosomal chromosome 
abnormalities at 0.25%.8 Other studies have shown that 
the prevalence of chromosomal abnormalities is 5% for in-
fertile men with oligozoospermia and 10–15% for those 
with azoospermia,9,10 and that, among all couples who un-
dergo ICSI, 4.3% of the men have chromosomal abnormal-
ities.11 Generally, azoospermic men are likely to possess 
sex chromosome abnormalities, and Klinefelter syndrome 
(KS) is the most prevalent sex chromosome disorder. In 
contrast, oligozoospermic men are likely to have auto-
somal chromosome abnormalities, which include chromo-
some translocation and inversion.12,13 With the increasing 
severity of spermatogenic failure, the possibility that the 
chromosome is abnormal also increases. Therefore, all in-
fertile couples who seek in vitro fertilization or ICSI be-
cause of spermatogenetic defects should receive standard 
chromosome karyotype analysis.
2.2. Klinefelter syndrome (47,XXY)
Klinefelter syndrome is not unusual in the male infertility 
clinic. The incidence of KS is approximately 1 in 500 (0.2%) 
among the male population, and it is the most common 
sex chromosome abnormality.14 The extra X chromosome 
can induce spermatogenic as well as steroidogenic failure, 
which results in testicular atrophy, azoospermia and 
gynecomastia. However, KS patients can present with a 
broad spectrum of phenotypes, professions, and socio-
economic statuses.15 The most common clinical character-
istics are small testes, elevated serum follicle-stimulating 
hormone level, and low or low-to-normal testosterone 
levels. Despite a low testosterone level, a patient’s libido 
is generally normal.15 However, KS patients might require 
androgen replacement therapy in later adulthood, because 
the testosterone level tends to decrease with age.
Approximately 3–10% of KS is mosaic form (46,XY/
47,XXY), and more than half of the patients still have sper-
matogenesis in their testes. Conversely, the remaining 
90% of KS is non-mosaic 47,XXY, and most patients pres-
ent with azoospermia. However, focal spermatogenesis 
might still exist in the atrophic testes of non-mosaic KS 
patients. Recent reports have demonstrated that 21–
69% of non-mosaic KS patients might have successful 
testicular sperm extraction (TESE),16,17 and younger pa-
tients (age < 35 years) might have a better chance of 
having spermatozoa.18 Consistent with these observa-
tions, Damani et al.19 have suggested a strategy of early 
TESE and sperm cryopreservation at puberty, given that 
spermatogenesis actively begins at this time and is grad-
ually lost as long as the compromised testicular environ-
ment continues.
The incidence of sex chromosome abnormalities in 
sperm retrieved from KS patients ranges from 0.9% to 
7.5%, compared with 0.4% in normal controls.20,21 In ad-
dition, the incidence of sex chromosome abnormalities 
in the embryo is only 3.1% in controls, compared with 
13.2% in KS patients.22 These results highlight the need 
for genetic counseling and preimplantation genetic diag-
nosis in these patients. Nevertheless, one recent review 
has revealed that only one KS karyotype in one fetus was 
noted among 39 reported successful pregnancies fathered 
by non-mosaic KS patients.23
2.3.  46,XX male syndrome
46,XX men are relatively rare in male infertility clinics, 
and the incidence is approximately 1 per 20,000 among 
the general population.19,24,25 In 90% of the 46,XX males, 
the paternal sex-determining region Y (SRY) gene is trans-
located to the X chromosome, or rarely, to the auto-
some.26 The other 10% of the SRY-negative 46,XX males 
are believed to have mutations/polymorphisms or gene 
expression defects, along with female gonadal develop-
ment, which results in testicular differentiation of bipo-
tential gonads and testosterone secretion.24 Testos terone 
is converted into dihydrotestosterone via the action of 
5α-reductase, which results in the development of male 
external genitalia. Given the lack of Y chromosome con-
taining the spermatogenesis-related genes, germ cells are 
not present in the testes of 46,XX males. Thus, neither 
diagnostic testicular biopsy nor TESE is recommended 
for these patients.
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2.4.  Chromosomal translocation and inversion
Chromosomal translocation accounts for 2–3% of male 
infertility. To date, over 50 different chromosomal trans-
locations have been reported to be associated with 
spermatogenic failure. Robertsonian translocation of 
chromosomes 13 and 14 is well known to result in oli-
goasthenoteratozoospermia.27 Certain translocations can 
interfere with prophase I pairing in meiosis and disrupt 
its progression, thus the patients might present with 
severe oligozoospermia or azoospermia.
Chromosomal inversion can be divided into pericen-
tric (around the centromere) or paracentric (beyond the 
centromere) inversion. If the genetic material is not lost, 
gained or altered by the inversion, there is no obvious ef-
fect on the phenotype of the individual. However, chro-
mosomal inversion could interfere with chromosome 
pairing in prophase I of meiosis, which results in disrup-
tion of meiosis, and subsequently, oligozoospermia or 
azoospermia. Loss or duplication of the genetic material 
produces abnormal gametes. Therefore, the risk of miscar-
riage and children born with chromosomal and congeni-
tal defects is high. Amniocentesis and preimplantation 
genetic diagnosis can be used preemptively to increase 
the chance of transferring only chromosomally normal 
embryos.28
3.  Y Chromosome Deletions
3.1.  Y chromosome deletion model
The human Y chromosome contains many amplicons that 
are non-X-transposed, non-X-degenerated, repetitive se-
quences with nearly complete identity in male-specific 
regions. Non-allelic homologous recombination between 
amplicons has been shown to generate deletions with 
resultant spermatogenic failure.29–31 Deletions of azoo-
spermia factors (AZFs) on the long arm of the Y chromo-
some (Yq) have been widely studied and recognized as 
the second most frequent genetic cause of spermato-
genic failure after KS.32 These genes are located in the 
proximal, middle and distal subregions of Yq11, and are 
designated as AZFa, AZFb and AZFc, respectively.33 Re-
cently, the deletion models have been revised according 
to the recombination mechanisms identified between 
palindromes P5 and P1.34,35 These are AZFa, P5/proximal 
P1, P5/distal P1, P4/distal P1, and AZFc (b2/b4).
3.2.  Detection of Y chromosome deletions
The European Academy of Andrology (EAA) and the 
European Molecular Genetics Quality Network (EMQN) 
have recommended a minimal set of primers for screen-
ing Y chromosome deletions, which includes six sequence-
tagged sites as a basic set of primers for diagnosis: sY84 
and sY86 for AZFa, sY127 and sY134 for AZFb, and sY254 
and sY255 for AZFc, with SRY and ZFY/ZFX as controls. 
The EAA/EMQN best practice guidelines state that this 
primer set enables the detection of all the clinically rel-
evant deletions and > 95% of the deletions in the three 
AZF regions.36 The EAA/EMQN protocol is widely accepted 
and supported by the American Urological Association, 
American Association of Bioanalysis, American Society 
for Reproductive Medicine, United Kingdom Human 
Fertilisation and Embryo Authority, and French Society 
for Human Genetics.
3.3.  Y Chromosome deletion status in Taiwan
In our institute, a gene-specific, five-marker panel is 
used to detect the Y chromosome deletion status in 
Taiwanese infertile men. From 2000 to 2005, a total of 
627 infertile men and 212 proven fertile controls were 
tested. Forty-one patients were found to have Y dele-
tions. These patients included three with AZFa (7%), 
eight with AZFb + c (20%), and 30 with AZFc deletions 
(73%).37,38 We also used a triple-blind study design to 
compare the efficacy of our five-marker panel protocol 
and the EAA/EMQN protocol. The results showed a con-
sistent deletion status between our protocol and that of 
the EAA/EMQN. Moreover, a review of > 4800 infertile 
patients has shown that Y chromosome deletion most 
frequently involves the AZFc region (60%), less frequently 
the AZFb region (25%), and least of all the AZFa interval 
(5%).39 Taken together, our data do not show an ethnicity-
specific deletion pattern of the Y chromosome in the 
Taiwanese population. AZFc (b2/b4) deletion was the 
most common deletion pattern in our series and others. 
The AZFc region is composed completely of amplicons, 
and homologous recombination between amplicons b2 
and b4 is probably one of the most common genetic 
causes of spermatogenic failure.40
The overall deletion frequency in our series was 6.5% 
(41 of 627). The deletion rate was 11.6% (34 of 293) in 
patients with sperm concentration < 106/mL or azoosper-
mia, 4.5% (5 of 110) in patients with sperm concentra-
tion between 1 ˜  106 and 5 ˜  106/mL, and 0.9% (2 of 
224) in patients with sperm concentration > 5 ˜  106/mL. 
Our findings are consistent with previous reports that 
Y chromosome deletions are found almost exclusively 
in patients with sperm concentration < 106/mL, and are 
extremely rare in those with a sperm concentra-
tion > 5 ˜  106/mL.39,40 Given the low deletion rate (0.9%) 
in this series and in others (0.7%),41 it is reasonable to 
set the threshold for Y chromosome deletion testing 
at < 5 ˜  106/mL or non-obstructive azoospermia.
3.4.  Genotype–phenotype correlation
In some studies including our own, attempts have been 
made at genotype–phenotype correlation, which have pro-
duced a general rule. Deletions of the AZFa, P5/proximal 
P1, P5/distal P1, P4/distal P1 regions are always associated 
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with the Sertoli cell-only syndrome testicular phenotype. 
These patients might not obtain any benefit from testic-
ular sperm retrieval. Conversely, deletion of the AZFc 
region can lead to oligozoospermia, testicular hyposper-
matogenesis or maturation arrest of postmeiotic germ 
cells. It is always possible to find sperm in the testes. 
Therefore, Y chromosome deletion status might be used as 
a predictor of successful sperm retrieval in infertile men.
4.  Congenital Bilateral Absence of Vas 
Deferens and CFTR Gene Mutations
4.1.  Congenital bilateral absence of vas deferens, 
cystic fibrosis and CFTR gene
Congenital bilateral absence of vas deferens (CBAVD) 
accounts for ∼2% of cases of male infertility and ∼6% of 
infertile men with obstructive azoospermia.42 It has also 
been reported that CBAVD is present in approximately 
95% of male patients with cystic fibrosis.43 From multi-
ple surveys in Caucasian populations, ∼66% of men with 
CBAVD carry mutations in the CFTR gene.44,45
Cystic fibrosis is a lethal autosomal recessive genetic 
disorder in Caucasians, which is characterized by chronic 
pulmonary inflammation, pancreatic exocrine insuffi-
ciency, elevated concentrations of electrolytes in sweat, 
chronic sinusitis, diabetes mellitus, liver cirrhosis, and 
CBAVD.36 The CFTR gene is located on chromosome 7 
(7q31–q32) and contains 27 exons. To date, > 1000 mu-
tations of CFTR genes have been found, and over two-
thirds of mutant alleles in cystic fibrosis patients are 
ΔF508 (in-frame deletion of phenylalanine at residue 508) 
and R117H (missense mutation in exon 4 with Arg117-
to-His).46–48 However, the routine mutation testing rec-
ommended by the American College of Medical Ge netics 
for cystic fibrosis patients is not adequate to detect the 
mutation status in CBAVD patients.49 To date, a number 
of published series in Caucasians have shown that poly-
morphic polythymidine tract in intron 8, in addition to 
ΔF508 and R117H, is associated with CBAVD pheno-
type.46,50–54
4.2.  Screening of CFTR mutation in Taiwan
The mutation spectrum of the CFTR gene in Taiwanese 
CBAVD patients has been extensively analyzed by Taipei 
Medical University Hospital.55,56 The results have shown 
that Taiwanese CBAVD patients do not carry any of the 
common CFTR mutations found in Caucasians, and that 
seven homozygous and seven heterozygous 5T alleles in 
the intron 8, polythymidine tract are present. The 5T al-
lele accounts for the majority (81%) of the mutant alle-
les in Taiwanese CBAVD. In addition to the polythymidine 
tract in intron 8, five mutations, including p.V201M, 
p.N287K, c.–8G>C (125G>C), p.M469I and p.S895N, have 
been found in five patients, and p.N287K, p.M469I and 
p.S895N are novel mutation sites. The overall frequency 
of CFTR mutant alleles in Taiwanese men with CBAVD is 
36% (26 out of 72 alleles).
4.3.  Risk of cystic fibrosis in offspring
With the development of assisted reproductive tech-
nique, infertile men with CBAVD are able to achieve 
paternity by using sperm retrieval and ICSI. CBAVD is 
linked to CFTR gene mutation; therefore, offspring have 
an associated increased risk of cystic fibrosis. The 
European Association of Urology guidelines on male in-
fertility confirm this probability. For a man with CBAVD, 
if his partner is found to be a carrier, the chance of a 
baby with cystic fibrosis is 25% if he is heterozygous or 
50% if he is homozygous. If his partner is negative for 
unknown mutations, her chance of being a carrier of an 
unknown mutation is about 0.4%, and the possibility of 
her heterozygous partner fathering a child with cystic fi-
brosis is approximately 1 in 410.57 Therefore, the detec-
tion of CFTR gene mutation status is crucial for a man 
with CBAVD and his partner prior to sperm retrieval 
and ICSI.
5.  Conclusion
Standard karyotype analysis should be offered to all men 
with oligozoospermia or non-obstructive azoospermia 
who are seeking fertility treatment. For men with severe 
oligozoospermia (< 5 ˜  106/mL) or non-obstructive azoo-
spermia, testing for Y chromosome deletion prior to ICSI 
is recommended. When a man has structural abnormali-
ties of the vas deferens (CBAVD or unilateral absence of 
the vas), it is important to test the couple for CFTR gene 
mutations. Genetic counseling is mandatory for all cou-
ples with genetic abnormalities, which might obviate 
the need for TESE, and could ultimately alter the plan for 
assisted reproductive techniques.
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